Twist Bioscience Corporation — Company profile
Healthcare · Diagnostics & Research · United States
Last price 152.78 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.58B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Details
| Name | Twist Bioscience Corporation |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 979 |
| Founded | 2013 |
| Ipo Date | 2018-10-31 |
| Ceo | Emily Leproust |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| Isin | US90184D1000 |
| Cusip | 90184D100 |
| Cik | 0001581280 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Emily Marine Leproust Ph.D. | Co-Founder, Board Chair and Chief Executive Officer |
| Dr. Patrick John Finn Ph.D. | President and Chief Operating Officer |
| Adam Laponis | Chief Financial Officer |
| Dennis Cho J.D. | Chief Legal Officer and Corporate Secretary |
| Paula Green | Senior Vice President of Human Resources |
| Robert F. Werner | Vice President and Chief Accounting Officer |
| Siyuan Chen | Chief Technology Officer |
| Dr. Michael Fero Ph.D. | Chief Information Officer |
| Dr. Colby Souders Ph.D. | Chief Scientific Officer |
| Nicole Moreno | Senior Vice President of Sales and Support |
Contact
| Address | 681 Gateway Boulevard, South San Francisco, California 94080, United States |
| Phone | 800 719 0671 |
| Website | https://www.twistbioscience.com |